Читать книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов - Страница 365

Due to the relative newness of stem cell therapies, safety information is difficult to come by. Challenges by study coordinators on how to best assess benefit and harm have led to problems with statistical meta-analyses (comparisons of one study to another). Participants in all clinical trials endure increased risk with the hope of it being outweighed by benefit; however, iASC (and stem cell therapies in general) may be particularly risky due to the inherent manner in which stem cells function.